Karen Addington, Chief Executive of JDRF in the UK, pays tribute to Steve Hitchins, former chairman of the type 1 diabetes charity, who died on 24 September, 2019:
“All of us here at JDRF UK and across the JDRF network of international charities are very sad to announce that Steve Hitchins, JDRF’s chairman from 2006-2013 and a wonderful friend, donor, supporter, lobbyist and volunteer, died unexpectedly last night.
“Steve travelled the length and breadth of the UK to support a huge number of our events and initiatives.
“Whether they took place in a meeting room or a remote field, Steve could always be relied upon to do whatever was needed to support JDRF to the absolute best of his ability. He attended many JDRF One Walks, Discovery Days, Parliamentary events and fundraising dinners in addition to donating a significant amount of his time to his governance role as our chairman.
“Steve was a fantastic source of great advice, had a great sense of humour, and helped to propel our organisation forward to where it is today. In collaboration with his wife, Baroness Sarah Ludford, Steve contributed enormously to our public affairs work and together they hosted many of our major donors and JDRF events at the House of Lords.
“Our profound condolences go to Sarah at this terribly sad time.
“Steve also served on our JDRF International Board, travelling whenever necessary to New York and straight back again, to represent the UK, share strategic ideas and collaborate with supporters, researchers and colleagues from our global teams.
“Steve himself lived with type 1 diabetes and as he understood first-hand the impact the condition can have, he was determined that JDRF should reach more people with type 1 with our community engagement and support work and raise as much money as possible for research to find the cure.
“Steve made a huge contribution in helping cure, treat and prevent type 1 diabetes and we will all miss him very much.”
Donate in Steve’s memory
To remember Steve, please give a gift in his memory by donating to support life-changing type 1 diabetes research.